Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.67 |
| ▸ | TGM1 | P22735 | 12/20 | 0.67 |
| ▸ | F13A1 | P00488 | 11/20 | 0.67 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10064223 | 0.91 | TGM2 (0.70) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL3971768 | 0.88 | TGM2 (0.69) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL5253097 | 0.88 | POLB (0.71) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL4235140 | 0.88 | TGM2 (0.67) | TGM2TGM1F13A1TGM3KMT2A | |
| SCHEMBL17277447 | 0.88 | TGM2 (0.69) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL26104923 | 0.88 | TGM2 (0.67) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL12061638 | 0.85 | TGM2 (0.63) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL1871457 | 0.85 | ALDH1A1 (0.70) | TGM2TGM1F13A1TGM3KMT2A | |
| SCHEMBL932229 | 0.83 | TGM2 (0.63) | TGM2TGM1F13A1TGM3MEN1 | |
| SCHEMBL25381627 | 0.83 | TGM2 (0.76) | TGM2TGM1F13A1TGM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695237-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4486453-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-118843616-A | Benzamide compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-10-25 | — | — | CN | disclosed |
| WO-2024213625-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| WO-2023166103-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2011060321-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | TGM2 2/4885TGM1 9/4885F13A1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.